Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: PDD vs PAD to Treat Initially Diagnosed MM [Phase 4]
A Phase 4 clinical trial update for using PDD vs PAD in initially diagnosed multiple myeloma is reported, with unknown status.
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 study of bendamustine with ixazomib and dexamethasone in relapsed/refractory multiple myeloma completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-01-22Clinical Trial Update: A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy [Phase 1, Phase 2]
Phase I/II study evaluating mis-matched immune cells (AlloStim) in patients with advanced hematological malignancies; trial completed.
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT [Phase 1]
Phase 1 trial exploring a calcineurin inhibitor-free graft-versus-host disease prevention regimen after related haploidentical peripheral bl…
-
CLINICAL_TRIALS trial_result · 2020-01-18Clinical Trial Update: Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma [Phase 4]
Phase 4 clinical trial update on MPV (low-dose bortezomib/melphalan/prednisone) in multiple myeloma; the study is terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-01-14Clinical Trial Update: Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden [Phase 2]
Phase 2 trial evaluating two stem cell dose regimens to reduce transplant-induced symptom burden in patients with multiple myeloma or primar…
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Irradiation-based Myeloablative Conditioning Followed by Treg/Tcon Immunotherapy in HSCT [Phase 2]
Phase 2 clinical trial evaluating irradiation-based myeloablative conditioning followed by regulatory T cell and conventional T cell immunot…
-
CLINICAL_TRIALS trial_result · 2020-01-09Clinical Trial Update: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma [Phase 3]
Phase 3 trial comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) with Lenalidomide and Dexamethasone (Rd) in previously untreated …
-
CLINICAL_TRIALS trial_result · 2020-01-02Clinical Trial Update: Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating the combination of ibrutinib with bortezomib and dexamethasone in relapsed/refractory multiple myeloma has complete…
-
CLINICAL_TRIALS trial_result · 2019-12-20Clinical Trial Update: Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating total-body irradiation and fludarabine phosphate followed by donor peripheral blood stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2019-12-17Clinical Trial Update: Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating three stem cell mobilization regimens in patients with multiple myeloma has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2019-12-13Clinical Trial Update: Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial updating ixazomib with thalidomide and dexamethasone in relapsed/refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2019-12-11Clinical Trial Update: MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial of Ixazomib (MLN9708) in combination with panobinostat and dexamethasone for multiple myeloma has completed with posted resu…
-
CLINICAL_TRIALS trial_result · 2019-12-11Clinical Trial Update: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial update for autologous CAR-T/TCR-T cell immunotherapy targeting multiple malignancies; current status is unknown.
-
CLINICAL_TRIALS trial_result · 2019-12-09Clinical Trial Update: Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant [Phase 2]
Phase 2 trial investigating sirolimus, cyclosporine, and mycophenolate mofetil to prevent graft-versus-host disease in patients with blood c…
-
CLINICAL_TRIALS trial_result · 2019-12-06Clinical Trial Update: Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients [Phase 3]
Phase 3 multinational trial compares isatuximab with pomalidomide and dexamethasone versus pomalidomide and dexamethasone in relapsed or ref…
-
CLINICAL_TRIALS trial_result · 2019-12-06Clinical Trial Update: Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma [Phase 4]
Phase 4 trial update on apixaban for primary prevention of venous thromboembolism in patients with multiple myeloma; results have been poste…
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 [Phase 2]
Phase 2 clinical trial update for masitinib in relapse/refractory multiple myeloma with t(4/14) translocation, FGFR3 expression status.
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma [Phase 4]
Phase 4 clinical trial update comparing RDD versus VDD in newly diagnosed multiple myeloma patients.
-
CLINICAL_TRIALS trial_result · 2019-11-21Clinical Trial Update: Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating carfilzomib with dexamethasone in Chinese patients with relapsed and refractory multiple myeloma has completed wi…
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma [Phase 3]
Phase 3 trial evaluating efficacy and safety of three thalidomide doses for relapsed/refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial update evaluating BCMA-PD1-CART cells for safety and efficacy in relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid [NA]
Clinical trial investigating simvastatin and zoledronic acid for overcoming chemotherapy resistance in refractory multiple myeloma; study te…
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2, Phase 3]
Phase 2/3 trial evaluating JNJ-63723283 in combination with daratumumab vs daratumumab alone in relapsed or refractory multiple myeloma has …
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 2]
Phase 2 trial updates safety and efficacy of single-agent CC-5013 in relapsed and refractory multiple myeloma.